Company Profile

Exavir Therapeutics Inc
Profile last edited on: 3/12/2024      CAGE: 9F4N0      UEI: EV9JGJL7VVF9

Business Identifier: Dedicated to transforming the lives of patients living with or at risk of HIV
Year Founded
2022
First Award
2023
Latest Award
2023
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2 Embarcadero Center
San Francisco, CA 94111
   (510) 691-3372
   media@exavirtx.com
   www.exavirtx.com
Location: Multiple
Congr. District: 11
County: San Francisco

Public Profile

Exavir Therapeutics is a biotechnology company dedicated to developing nanomedicines for chronic disorders in virology and CNS, beginning with ultra-long-acting integrase inhibitors for HIV Treatment and HIV PrEP.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2024 2 NIH $2,049,976
Project Title: XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies

Key People / Management

  Alborz Yazdi -- co-founder and CEO

  Mark Cockett -- Chief Scientific Advisor

  Howard E Gendelman -- co-founder

  Janet Gunzner-Toste

  Brian Kearney -- Manager

Company News

There are no news available.